Summary
The key messages in 20 points 1. Blood pressure, epidemiology and risk. Globally, over 1 billion people have hypertension. As populations age and adopt more sedentary lifestyles, the worldwide prevalence of hypertension will continue to rise towards 1.5 billion by 2025. Elevated blood pressure (BP) is the leading global contributor to premature death, accounting for almost 10 million deaths in 2015, 4.9 million due to ischaemic heart disease and 3.5 million due to stroke. Hypertension is also a major risk factor for heart failure, atrial fibrillation, chronic kidney disease (CKD), peripheral artery disease (PAD) and cognitive decline. 2. Definition of hypertension. The classification of BP and the definition of hypertension is unchanged from previous European guidelines, and is defined as an office SBP at least 140 mmHg and/or DBP at least 90 mmHg, which is equivalent to a 24-h ABPM average of at least 130/80 mmHg, or a home blood pressure monitoring (HBPM) average at least 135/ 85 mmHg.
Screening and diagnosis of hypertension.
Hypertension is usually asymptomatic (hence the term 'silent killer'). Because of its high prevalence, screening programmes should be established to ensure that BP is measured in all adults, at least every 5 years and more frequently in people with a high-normal BP. When hypertension is suspected because of an elevated screening BP, the diagnosis of hypertension should be confirmed either by repeated office BP measurements, over a number of visits, or by out-of-office BP measurement using 24-h ABPM or by HBPM. 4. The importance of cardiovascular risk assessment and detection of HMOD. Other cardiovascular risk factors such as dyslipidaemia and metabolic syndrome frequently cluster with hypertension. Thus, unless the patient is already at high or very high risk due to established CVD, formal cardiovascular risk assessment is recommended using the SCORE system. It is important to recognize, however, that the presence of HMOD, especially left ventricular hypertrophy (LVH), chronic kidney disease (CKD) or advanced retinopathy, further increases the risk of cardiovascular morbidity and mortality, and should be screened for as part of risk assessment in hypertensive patients because the SCORE system alone may underestimate their risk. 5. Think -could this patient have secondary hypertension? For most people with hypertension, no underlying cause will be detected. It is increasingly recognized that biological rather than chronological age, as well as consideration of frailty and independence, are important determinants of the tolerability of and likely benefit from BP-lowering medications. It is important to note that even in the very old (i.e. > 80 years), BP-lowering therapy reduces mortality, stroke and heart failure. Thus, these patients should not be denied treatment, or have treatment withdrawn simply on the basis of age. For people more than 80 years of age who have not yet received treatment for their BP, treatment is recommended when their office SBP is at least 160 mmHg, provided that the treatment is well tolerated. 9. How low should SBP be lowered? This has been a hotly debated topic. A key discussion point is the balance of potential benefits versus potential harm or adverse effects. This is especially important whenever BP targets are lowered, as there is a greater potential for harm to exceed benefit. Thus, in this guideline, we recommend a target range. The evidence strongly suggests that lowering office SBP to less than 140 mmHg is beneficial for all patient groups, including independent older patients. There is also evidence to support targeting SBP to 130 mmHg for most patients, if tolerated. Even lower SBP levels (<130 mmHg) will be tolerated and potentially beneficial for some patients, especially to further reduce the risk of stroke. SBP should not be targeted to below 120 mmHg because the balance of benefit versus harm becomes concerning at these levels of treated SBP. 10. Blood pressure targets in old and very old patient. As discussed above, independence, frailty and comorbidities will all influence treatment decisions, especially in older (! 65 years) and very old (> 80 years) patients. The desired SBP target range for all patients aged more than 65 years is less than 140 mmHg but not less than 130 mmHg. This is lower than in previous guidelines and may not be achievable in all older patients, but any BP lowering towards this target is likely to be beneficial provided that the treatment is well tolerated. 11. Blood pressure targets in patients with diabetes and/or chronic kidney disease. The BP-treatment targets for patients with diabetes or kidney disease have been a moving target in previous guidelines because of seemingly contradictory results from major outcome trials and meta-analyses. For diabetes, targeting the SBP to less than 140 mmHg and towards 130 mmHg, as recommended for all other patient groups, is beneficial on major outcomes. Moreover, targeting SBP to less than 130 mmHg, for those who will tolerate it, may further reduce the risk of stroke but not other major outcomes. SBP should not be lowered below 120 mmHg. For patients with CKD, the evidence suggests that the target BP range should be less than 140 mmHg but not less than 130 mmHg. 12. How low should DBP be lowered? The optimal DBP target has been less well defined, but a DBP target of less than 80 mmHg is recommended. Some patients with stiff arteries and isolated systolic hypertension will already have DBP levels below this target. These are high-risk patients and the low DBP should not discourage treatment of their elevated SBP to the recommended target, provided that treatment is well tolerated. 13. The need to do better on blood pressure control. A key message in this guideline is the need to do better at improving BP control rates. Despite the overwhelming evidence of treatment benefit, on average, less than 50% of patients with treated hypertension achieve a SBP target of less than 140 mmHg. Physician inertia (inadequate up-titration of treatment, especially from monotherapy) and poor patient adherence to treatment (especially when based on multiple pills) are now recognized as the major factors contributing to poor BP control. 14. Start treatment in most patients with two drugs, not one. Monotherapy is usually inadequate therapy for most people with hypertension; this will be especially true now that the BP-treatment targets for many patients are lower than in previous guidelines. This guideline sets out to normalize the concept that initial therapy for the majority of patients with hypertension should be with a combination of two drugs, not a single drug. The only exception would be in a limited number of patients with a lower baseline BP close to their recommended target, who might achieve that target with a single drug, or in some frailer old or very old patients, in whom more gentle reduction of BP may be desirable. Evidence suggests that this approach will improve the speed, efficiency and consistency of initial BP lowering and BP control, and is well tolerated by patients. 15. A single pill strategy to treat hypertension.
Poor adherence to longer-term BP lowering medication is now recognized as a major factor contributing to poor BP control rates. Research has shown a direct correlation between the number of BP-lowering pills and poor adherence to medications. Moreover, SPC therapy has been shown to improve adherence to treatment. SPC therapy is now the preferred strategy for initial two-drug combination treatment of hypertension and for three-drug combination therapy when required. This will control the BP in most patients with a single pill and could transform BP control rates. 16. A simplified drug-treatment algorithm. We have simplified the treatment strategy so that patients with uncomplicated hypertension and many patients with a variety of comorbidities (e.g. HMOD, diabetes, PAD or cerebrovascular disease) receive similar medication. We recommend a combination of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) with a CCB or thiazide/thiazide-like diuretic as initial therapy for most patients. For those requiring three drugs, we recommend a combination of an ACE inhibitor or ARB with a CCB and a thiazide/ thiazide-like diuretic. We recommend beta-blockers be used when there is a specific indication for their use (e.g. angina, postmyocardial infarction, HFrEF or when heart-rate control is required). 17. Hypertension in women and in pregnancy. For hypertensive patients at moderate CVD risk or higher, or those with established CVD, BP lowering alone will not optimally reduce their risk. These patients would also benefit from statin therapy, which further reduces the risk of a myocardial infarction by approximately one-third and stroke by approximately one-quarter, even when BP is controlled. Similar benefits have been seen in hypertensive patients at the border between low and moderate risk. Thus, many more hypertensive patients would benefit from statin therapy than are currently receiving this treatment.
INTRODUCTION
These 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines for the management of arterial hypertension are designed for adults with hypertension, that is aged at least 18 years. The purpose of the review and update of these guidelines was to evaluate and incorporate new evidence into the guideline recommendations. The specific aims of these guidelines were to produce pragmatic recommendations to improve the detection and treatment of hypertension, and to improve the poor rates of BP control by promoting simple and effective treatment strategies.
Principles
These fundamental principles are to base recommendations on properly conducted studies, identified from an extensive review of the literature; to give the highest priority to data from randomized controlled trials (RCTs); and to also consider well conducted meta-analyses of RCTs as strong evidence. This contrasts with network meta-analyses, which we do not consider to have the same level of evidence because many of the comparisons are nonrandomized; to recognize that RCTs cannot address many important questions related to the diagnosis, risk stratification and treatment of hypertension, which can be addressed by observational or registrybased studies of appropriate scientific calibre; to grade the level of scientific evidence and the strength of recommendations according to ESC recommendations; to recognize that opinions may differ on key recommendations, which are resolved by voting; and to recognize that there are circumstances in which there is inadequate or no evidence, but the question is important for clinical practice and cannot be ignored. In these circumstances, we resort to pragmatic expert opinion and endeavour to explain its rationale.
What is new and what is changed in the 2018 European Society of Cardiology/European Society of Hypertension hypertension guidelines?
Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ from the 2013 ones in several points indicated as follows (Fig. 1 ).
New concepts
Blood pressure measurement 1. Wider use of out-of-office BP measurement with ABPM and/or HBPM, especially HBPM, as an option to confirm the diagnosis of hypertension, detect white coat and masked hypertension and monitor BP control.
Less conservative treatment of blood pressure in older and very old patients 1. Lower BP thresholds and treatment targets for older patients, with an emphasis on considerations of biological rather than chronological age (i.e. the importance of frailty, independence and the tolerability of treatment). 2. Recommendation that treatment should never be denied or withdrawn on the basis of age, provided that treatment is tolerated.
A SPC treatment strategy to improve blood pressure control 1. Preferred use of two-drug combination therapy for the initial treatment of most people with hypertension.
2.
A single-pill treatment strategy for hypertension with the preferred use SPC therapy for most patients. 3. Simplified drug-treatment algorithms with the preferred use of an ACE inhibitor or ARB combined with a CCB or/and a thiazide/thiazide-like diuretic as the core treatment strategy for most patients, with betablockers used for specific indications.
New target ranges for blood pressure in treated patients 1. Target BP ranges for treated patients to better identify the recommended BP target and lower safety boundaries for treated BP, according to a patient's age and specific comorbidities.
Detecting poor adherence to drug therapy 1. A strong emphasis on the importance of evaluating treatment adherence as a major cause of poor BP control.
A key role for nurses, pharmacists in the longer-term management of hypertension 1. The important role of nurses and pharmacists in the education, support and follow-up of 2. Treated hypertensive patients are emphasized as part of the overall strategy to improve BP control.
DEFINITIONS AND CLASSIFICATIONS
The relationship between BP and cardiovascular and renal events is continuous, making the distinction between normotension and hypertensionÀbased on cut-off BP val-uesÀsomewhat arbitrary. 'Hypertension' is defined as the level of BP at which the benefits of treatment (either with lifestyle interventions or drugs), unequivocally outweigh the risks of treatment, as documented by clinical trials. This evidence has been reviewed and provides the basis for the recommendation that the classification of BP and definition of hypertension remain unchanged from previous ESH/ESC guidelines (Fig. 2 ). 
DIAGNOSTIC EVALUATION

Evaluation of the cardiovascular risk
Measurement of blood pressure
Auscultatory or oscillometric semiautomatic or automatic sphygmomanometers are the preferred method for measuring BP in the doctor's office. These devices should be validated according to standardized conditions and protocols. BP can be highly variable, thus the diagnosis of hypertension should not be based on a single set of BP readings at a single office visit, unless the BP is substantially increased (e.g. grade 3 hypertension) and there is clear evidence of HMOD (e.g. hypertensive retinopathy with exudates and haemorrhages, or LVH, or vascular or renal damage). For all others (i.e. almost all patients), repeat BP measurements at repeat office visits have been a long-standing strategy to confirm a persistent elevation in BP, as well as for the classification of the hypertension status in clinical practice and RCTs.
White-coat hypertension refers to the untreated condition in which BP is elevated in the office, but is normal when measured by ABPM, HBPM, or both. Conversely, 'masked hypertension' refers to untreated patients in whom the BP is normal in the office, but is elevated when measured by HBPM or ABPM. The term 'true normotension' is used when both office and out-of-office BP measurements are normal, and 'sustained hypertension' is used when both are abnormal. In white-coat hypertension, the difference between the higher office and the lower out-of-office BP is referred to as the 'white-coat effect' and is believed to mainly reflect the pressor response to an alerting reaction elicited by office BP measurements by a doctor or a nurse, although other factors are probably also involved (Fig. 6) .
These guidelines also support the use of out-of-office BP (i.e. HBPM and/or ABPM) ( Figs. 7-10) as an alternative strategy to repeated office BP measurements, to confirm the diagnosis of hypertension, when these measurements are logistically and economically feasible. This approach can provide important supplementary clinical information, for example detecting white-coat hypertension, which should be suspected, especially in people with grade 1 hypertension on office BP measurement and in whom there is no evidence of HMOD or CVD. A particular challenge is the detection of masked hypertension. Masked hypertension is more likely in people with a BP in the high-normal range in whom out-of-office BP should be considered to exclude masked hypertension. Out-of-office BP measurements are also indicated in other specific circumstances (Figs. 7-9 ).
All adults should have their BP recorded in their medical record and be aware of their BP, and further screening should be undertaken at regular intervals with the frequency dependent on the BP level as illustrated in Fig. 10 . 
Clinical evaluation
The information to be obtained at the time of the first diagnosis of hypertension is indicated in Figs. 11-14 .
TREATMENT OF HYPERTENSION
The routine treatment of hypertension involves lifestyle interventions for all patients (including those with high normal BP) and drug therapy for most patients.
All guidelines agree that patients with grade 2 or 3 hypertension should receive antihypertensive drug treatment alongside lifestyle interventions. Guidelines are also consistent in recommending that patients with grade 1 hypertension and high cardiovascular risk or HMOD should be treated with BP-lowering drugs. There has been less consistency about whether BP-lowering drugs should be offered to patients with grade 1 hypertension and low-to-moderate cardiovascular risk or grade 1 hypertension in older patients (> 60 years), or the need for BP-lowering drug treatment in patients with high-normal BP levels. This uncertainty relates to the fact that low-risk patients with high-normal BP or grade 1 hypertension have rarely been included in RCTs, and that in older patients, RCTs have invariably recruited patients with at least grade 2 hypertension.
Drug treatment strategy and blood pressure targets (Figs 15-20) The level to which BP should be lowered with drug treatment will depend on the patients' age, comorbidities and tolerability of treatment. Corresponding BP targets for home and ambulatory BP are less well established, but an office BP less than 130 mmHg probably corresponds to a FIGURE 11 Key information to be collected in personal and family medical history (1). AF, atrial fibrilation; CKD, chronic kidney disease; CVD cardiovascular disease; HMOD, hypertension-mediated organ damage; TIA, transient ischaemic attack.
FIGURE 12 Key information to be collected in personal and family medical history (2) . 24-h ABPM SBP of less than 125 mmHg and a home average SBP of less than 130 mmHg.
The core algorithm is also appropriate for most patients with HMOD, cerebrovascular disease, diabetes or peripheral artery disease.
Drug treatment strategy for specific clinical situations: coronary heart disease, chronic kidney disease, heart failure, atrial fibrillation (Figures 21-25) 
Device-based therapy for hypertension
The actual recommendation is the following: 'Use of device-based therapies is not recommended for the routine treatment of hypertension, unless in the context of clinical studies and RCTs, until further evidence regarding their safety and efficacy becomes available'.
Resistant hypertension
Hypertension is defined as resistant to treatment when the recommended treatment strategy fails to lower office SBP and DBP values to below 140 and/or 90 mmHg, respectively, and the inadequate control of BP is confirmed by ABPM or HBPM, in patients whose adherence to therapy has been confirmed ( Figs. 26 and 27) . The recommended treatment strategy should include appropriate lifestyle measures and treatment with optimal or best-tolerated doses of three or more drugs that should include a diuretic and typically an ACE inhibitor or ARB, and a CCB. 
FIGURE 21
Drug-treatment strategy for hypertension and coronary artery disease. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CVD, cardiovascular disease.
FIGURE 22
Drug-treatment strategy for chronic kidney disease. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CVD, cardiovascular disease. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CKD, chronic kidney disease.
FIGURE 23
Drug-treatment strategy for hypertension and heart failure with reduced ejection fraction. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
FIGURE 24
Drug-treatment strategy for hypertension and atrial fibrillation. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; DHP, dihydropyridine.
Secondary hypertension
Secondary hypertension is hypertension due to an identifiable cause, which may be treatable with an intervention specific to the cause (Figs. 28-31) . A high index of suspicion and early detection of secondary hypertension is important because interventions may be curative, especially in younger patients.
Hypertension emergency
Hypertension emergencies are situations in which severe hypertension (grade 3) is associated with acute HMOD, which is often life-threatening and requires immediate but careful intervention to lower BP, usually with intravenous (i.v.) therapy ( Figs. 32 and 33) . The rate and magnitude of increase in BP may be at least as important as the absolute level of BP in determining the magnitude of organ injury.
Treatment recommendations in special situations 
FOLLOW-UP OF PATIENTS
Frequency of visits
After the initiation of antihypertensive drug therapy, it is important to review the patient at least once within the first 2 months to evaluate the effects on BP and assess possible side effects until BP is under control. The frequency of review will depend on the severity of hypertension, the urgency to achieve BP control and the patient's comorbidities.
Patients with high-normal BP or white-coat hypertension frequently have additional risk factors, including HMOD, and have a higher risk of developing sustained hypertension. Thus, even when untreated, they should be scheduled for regular follow-up (at least annual visits) to measure office and out-of-office BP, as well as to check the cardiovascular risk profile.
Adherence to therapy (Fig. 43) There is growing evidence that poor adherence to treat-mentÀin addition to physician inertia (i.e. lack of therapeutic action when the patient's BP is uncontrolled)Àis the most important cause of poor BP control. Nonadherence to antihypertensive therapy correlates with higher risk of cardiovascular events.
Note: The levels of evidence for each of the recommendations presented in the figures can be found in the original FIGURE 29 Common causes of secondary hypertension (1). CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PAD, peripheral artery disease.
FIGURE 30
Common causes of secondary hypertension (2) . ABI, ankle-brachial index.
FIGURE 37
Hypertension in chronic kidney disease. CCB, calcium channel blockers; CKD, chronic kidney disease; RAS, renin-angiotensin system.
FIGURE 38
Hypertension in coronary artery disease. CAD, coronary artery disease; CCB, calcium channel blockers.
FIGURE 39
Hypertension in left ventricular hypertrophy and heart failure. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; LVH, left ventricular hypertrophy; RAS, renin-angiotensin system.
